Hepion Pharmaceuticals Inc (HEPA) - Net Assets
Based on the latest financial reports, Hepion Pharmaceuticals Inc (HEPA) has net assets worth $2.67 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.07 Million) and total liabilities ($402.40K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read total liabilities of Hepion Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.67 Million |
| % of Total Assets | 86.89% |
| Annual Growth Rate | N/A |
| 5-Year Change | -97.13% |
| 10-Year Change | 102.46% |
| Growth Volatility | 238.75 |
Hepion Pharmaceuticals Inc - Net Assets Trend (2012–2025)
This chart illustrates how Hepion Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore Hepion Pharmaceuticals Inc (HEPA) total assets for the complete picture of this company's asset base.
Annual Net Assets for Hepion Pharmaceuticals Inc (2012–2025)
The table below shows the annual net assets of Hepion Pharmaceuticals Inc from 2012 to 2025. For live valuation and market cap data, see market value of Hepion Pharmaceuticals Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $2.67 Million | +243.16% |
| 2024-12-31 | $-1.86 Million | -125.59% |
| 2023-12-31 | $7.28 Million | -85.40% |
| 2022-12-31 | $49.86 Million | -46.39% |
| 2021-12-31 | $93.00 Million | +129.50% |
| 2020-12-31 | $40.52 Million | +159.47% |
| 2019-12-31 | $15.62 Million | +690.70% |
| 2018-12-31 | $1.98 Million | -46.67% |
| 2017-12-31 | $3.70 Million | +181.06% |
| 2016-12-31 | $1.32 Million | -61.69% |
| 2015-12-31 | $3.44 Million | +217.25% |
| 2014-12-31 | $-2.93 Million | 0.00% |
| 2013-12-31 | $-2.93 Million | -1987.75% |
| 2012-12-31 | $-140.50K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hepion Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 24595716100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.16K | 0.04% |
| Other Comprehensive Income | $8.35K | 0.31% |
| Other Components | $248.76 Million | 9325.26% |
| Total Equity | $2.67 Million | 100.00% |
Hepion Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Hepion Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Triad Group PLC
LSE:TRD
|
$604.39K |
|
LeoNovus Inc
V:LTV
|
$604.78K |
|
Gear4music (Holdings) Plc
LSE:G4M
|
$606.17K |
|
IRWIN NATURALS INC.
F:97X
|
$606.63K |
|
Starwood European Real Estate Finance Ltd
LSE:SWEF
|
$603.58K |
|
Waseco Resources Inc.
V:WRI
|
$603.03K |
|
Schroder BSC Social Impact Trust PLC
LSE:SBSI
|
$600.17K |
|
Ecoclime Group AB Series B
ST:ECC-B
|
$598.77K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hepion Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,863,338 to 2,667,547, a change of 4,530,885.
- Net loss of 8,277,850 reduced equity.
- Other factors increased equity by 12,808,735.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.28 Million | -310.32% |
| Other Changes | $12.81 Million | +480.17% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Hepion Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.22x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-8742.69 | $0.06 | x |
| 2014-12-31 | $-128142.42 | $0.06 | x |
| 2015-12-31 | $88522.11 | $0.06 | x |
| 2016-12-31 | $27267.80 | $0.06 | x |
| 2017-12-31 | $26784.01 | $0.06 | x |
| 2018-12-31 | $10740.98 | $0.06 | x |
| 2019-12-31 | $7644.00 | $0.06 | x |
| 2020-12-31 | $4187.29 | $0.06 | x |
| 2021-12-31 | $1323.00 | $0.06 | x |
| 2022-12-31 | $654.03 | $0.06 | x |
| 2023-12-31 | $1.83 | $0.06 | x |
| 2024-12-31 | $-15.16 | $0.06 | x |
| 2025-12-31 | $0.28 | $0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hepion Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -310.32%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.15x
- Recent ROE (-310.32%) is below the historical average (-291.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-828.92K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.99 Million |
| 2015 | -417.20% | 0.00% | 0.00x | 1.56x | $-14.69 Million |
| 2016 | -1290.14% | 0.00% | 0.00x | 9.95x | $-17.13 Million |
| 2017 | -405.66% | 0.00% | 0.00x | 3.04x | $-15.39 Million |
| 2018 | -478.43% | 0.00% | 0.00x | 4.15x | $-9.65 Million |
| 2019 | -45.06% | 0.00% | 0.00x | 1.32x | $-8.60 Million |
| 2020 | -50.23% | 0.00% | 0.00x | 1.20x | $-24.41 Million |
| 2021 | -35.19% | 0.00% | 0.00x | 1.11x | $-42.02 Million |
| 2022 | -84.64% | 0.00% | 0.00x | 1.21x | $-47.19 Million |
| 2023 | -671.99% | 0.00% | 0.00x | 2.49x | $-49.65 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.01 Million |
| 2025 | -310.32% | 0.00% | 0.00x | 1.15x | $-8.54 Million |
Industry Comparison
This section compares Hepion Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hepion Pharmaceuticals Inc (HEPA) | $2.67 Million | 0.00% | 0.15x | $604.26K |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Hepion Pharmaceuticals Inc
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as … Read more